The assessment of antiangiogenic and antivascular therapies in early-stage clinical trials using magnetic resonance imaging: issues and recommendations.
Vascular and angiogenic processes provide an important target for novel cancer therapeutics. Dynamic contrast-enhanced magnetic resonance imaging is being used increasingly to noninvasively monitor the action of these therapeutics in early-stage clinical trials. This publication reports the outcome of a workshop that considered the methodology and design of magnetic resonance studies, recommending how this new tool might best be used.
Leach
M O
MO
Cancer Research UK Clinical Magnetic Resonance Research Group, Institute of Cancer Research, Royal Marsden Hospital, Sutton, Surrey, UK. martin.leach@icr.ac.uk
Brindle
K M
KM
Evelhoch
J L
JL
Griffiths
J R
JR
Horsman
M R
MR
Jackson
A
A
Jayson
G C
GC
Judson
I R
IR
Knopp
M V
MV
Maxwell
R J
RJ
McIntyre
D
D
Padhani
A R
AR
Price
P
P
Rathbone
R
R
Rustin
G J
GJ
Tofts
P S
PS
Tozer
G M
GM
Vennart
W
W
Waterton
J C
JC
Williams
S R
SR
Workman
P
P
D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D005069:Evaluation Studies as Topic; D008279:Magnetic Resonance Imaging; D009369:Neoplasms / Q000098:blood supply* / Q000188:drug therapy*; D015203:Reproducibility of Results; D009626:Terminology as Topic
D020533:Angiogenesis Inhibitors; D000970:Antineoplastic Agents